Literature DB >> 7708117

Differential effects of 3-PPP enantiomers on extracellular dopamine concentration in the caudate-putamen and nucleus accumbens of rats.

R E See1.   

Abstract

The ability of the enantiomers of 3-PPP (3-(3-hydroxyphenyl)-N-n-propylpiperidine) to modify the extracellular concentration of dopamine (DA) in the caudate-putamen and the nucleus accumbens of awake rats was assessed using intracranial microdialysis. The enantiomers and the racemate were directly infused at 3 incremental concentrations (1-100 microM) or systematically administered by subcutaneous injection (10 mg/kg). Both systemic administration and direct infusion of (-)3-PPP at the highest concentration (100 microM) significantly increased extracellular DA in both brain regions. This increase was also seen in the presence of higher extracellular DA levels following reuptake inhibition by nomifensine (10 microM). In contrast to the effects of (-)3-PPP, systemic administration of both (+)3-PPP and (+/-)3-PPP decreased DA levels. Infusion of (+/-)3-PPP led to slight increases in DA levels in both brain regions at the highest concentration (100 microM), while (+)3-PPP at 100 microM also produced a significant increase in the caudate-putamen, but not in the nucleus accumbens. However, in the presence of nomifensine-induced elevations in extracellular DA, (+)3-PPP produced a significant decrease in DA concentrations in both brain regions. These results support previous findings that the enantiomers of 3-PPP show unique profiles in their in vivo effects on DA terminal functions. Furthermore, these effects are dependent on the mode of 3-PPP administration, the brain region in which DA overflow is measured, and the level of basal extracellular DA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7708117     DOI: 10.1007/bf00169364

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  29 in total

1.  Regional differences in the regulation of acetylcholine release upon D2 dopamine and N-methyl-D-aspartate receptor activation in rat nucleus accumbens and neostriatum.

Authors:  J M Henselmans; J C Stoof
Journal:  Brain Res       Date:  1991-12-06       Impact factor: 3.252

2.  Enantiomers of monohydroxy-2-aminotetralin derivatives and their activity at dopamine autoreceptors as studied by brain dialysis.

Authors:  W Timmerman; P G Tepper; D Dijkstra; H Stoelwinder; C J Grol; B H Westerink; A S Horn
Journal:  Eur J Pharmacol       Date:  1991-06-25       Impact factor: 4.432

3.  In vivo assessment of release and metabolism of dopamine in the ventrolateral striatum of awake rats following administration of dopamine D1 and D2 receptor agonists and antagonists.

Authors:  R E See; B A Sorg; M A Chapman; P W Kalivas
Journal:  Neuropharmacology       Date:  1991-12       Impact factor: 5.250

4.  Regional differences in chronic neuroleptic effects on extracellular dopamine activity.

Authors:  R E See; M A Chapman; C E Murray; M Aravagiri
Journal:  Brain Res Bull       Date:  1992 Sep-Oct       Impact factor: 4.077

5.  Schizophrenic symptoms improve with apomorphine.

Authors:  C A Tamminga; M H Schaffer; R C Smith; J M Davis
Journal:  Science       Date:  1978-05-05       Impact factor: 47.728

6.  Differential effects of the stereoisomers of 3PPP on dopaminergic and cholinergic neurotransmission in superfused slices of the corpus striatum.

Authors:  S Arbilla; S Z Langer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-08       Impact factor: 3.000

7.  Effects of D-2 agonists on the release of dopamine: localization of the mechanism of action.

Authors:  W Timmerman; J B De Vries; B H Westerink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-12       Impact factor: 3.000

8.  Dopamine uptake is differentially regulated in rat striatum and nucleus accumbens.

Authors:  C Missale; L Castelletti; S Govoni; P F Spano; M Trabucchi; I Hanbauer
Journal:  J Neurochem       Date:  1985-07       Impact factor: 5.372

9.  Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats.

Authors:  A Imperato; G Tanda; R Frau; G Di Chiara
Journal:  J Pharmacol Exp Ther       Date:  1988-04       Impact factor: 4.030

10.  BMY-14802 reverses the reduction of striatal dopamine release induced by (+)-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine.

Authors:  A Kanzaki; K Okumura; H Ujike; K Tsuchida; K Akiyama; S Otsuki
Journal:  J Neural Transm Gen Sect       Date:  1992
View more
  1 in total

1.  Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion.

Authors:  Alan L Pehrson; Bita Moghaddam
Journal:  Psychopharmacology (Berl)       Date:  2010-06-29       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.